麝香通心滴丸药物作用机制和药物靶点的研究进展
|
摘要
麝香通心滴丸的药物作用机制主要是降低炎性因子、改善内皮功能、抗凋亡、抑制RAAS系统、稳定斑块、改善心肌纤维化,其药物作用靶点主要是e NOS、MicroRNAs、P13K/Akt、Lp-PLA2。中医药作为冠状动脉粥样硬化性心脏病(简称冠心病)的特色治疗方式,对冠心病的防治有独特的优势。目前,对麝香通心滴丸防治冠心病的机制和药物作用靶点研究不断增加,但因中医药研究技术有限,缺乏系统化和标准化的研究方法,导致其机制和药物靶点的精准研究受到较大限制。另一方面,麝香通心滴丸的药物作用机制和药物靶点进一步研究是建立在冠心病机制研究进展的基础上,伴随着冠心病机制和相关药物靶点进一步研究,麝香通心滴丸的研究将更加深入、全面。
The pharmacological mechanism of Thyme Heart-Dredging Dropping Pills is mainly to reduce inflammatory factors,improve endothelial function,resist apoptosis,inhibit RAAS system,stabilize plaque and improve myocardial fibrosis. Its main targets are eN OS,microRNAs,P13 K/Akt and Lp-PLA2. As a characteristic treatment of coronary heart disease,TCM has unique advantages in the prevention and treatment of coronary heart disease. At present,the research on the mechanism and drug targets of Thyme Heart-Dredging Dropping Pills in the prevention and treatment of coronary heart disease is increasing. However,due to the limited research technology of TCM and lack of systematic and standardized research methods,the precise study of its mechanism and drug targets is greatly limited. On the other hand,the further study on the mechanism and target of Thyme Heart-Dredging Dropping Pills is based on the research progress of the mechanism of coronary heart disease. With the further study on the mechanism of coronary heart disease and related drug targets,the study of Thyme Heart-Dredging will be deeper and comprehensive.
The pharmacological mechanism of Thyme Heart-Dredging Dropping Pills is mainly to reduce inflammatory factors,improve endothelial function,resist apoptosis,inhibit RAAS system,stabilize plaque and improve myocardial fibrosis. Its main targets are eN OS,microRNAs,P13 K/Akt and Lp-PLA2. As a characteristic treatment of coronary heart disease,TCM has unique advantages in the prevention and treatment of coronary heart disease. At present,the research on the mechanism and drug targets of Thyme Heart-Dredging Dropping Pills in the prevention and treatment of coronary heart disease is increasing. However,due to the limited research technology of TCM and lack of systematic and standardized research methods,the precise study of its mechanism and drug targets is greatly limited. On the other hand,the further study on the mechanism and target of Thyme Heart-Dredging Dropping Pills is based on the research progress of the mechanism of coronary heart disease. With the further study on the mechanism of coronary heart disease and related drug targets,the study of Thyme Heart-Dredging will be deeper and comprehensive.
引文
[1]张琼瑜,陈泽涛.麝香保心丸在心肌梗塞治疗中的应用进展[J].西部中医药,2014,27(12):147-149.
[2]付长庚,高铸烨,王培利,等.冠心病血瘀证诊断标准研究[J].中国中西医结合杂志,2015,32(9):1285-1286.
[3]曹洪涛.心血管疾病防治的中医药优势[J].西部中医药,2016,29(10):139-141.
[4] GOROG D. Coronary Heart Disease[M]. The Interventional Cardiology Training Manual. Cham:Springer International Publishing,2018:1-11.
[5]黄延锦,张平,曾颖.冠心病高危人群疾病知识认知水平及影响因素分析[J].中国护理管理,2015,13(1):51-54.
[6]韩芬,戴国华,赵晨,等. 386例冠心病心律失常住院患者中医药治疗情况调查分析[J].西部中医药,2015,28(3):86-89.
[7]田华.心电图对冠心病的诊疗意义[J].江苏实用心电学杂志,2013,22(5):823-826.
[8]刘东华,王士凯,印建荣,等.麝香通心滴丸用于稳定型心绞痛的疗效分析[J].医学理论与实践,2017,30(24):3631-3633.
[9]刘建平,廖火城,刘凌,等.麝香通心滴丸对心脏X综合征患者治疗作用的临床观察[J].中国医药科学,2018,8(12):231-233.
[10]李文华,吴晓军,李桂新,等.麝香通心滴丸治疗冠心病心绞痛的系统评价[J].西北国防医学杂志,2018,39(5):281-284.
[11]汪志忠,黎红华.动脉粥样硬化与炎性因子[J].中国神经免疫学和神经病学杂志,2011,18(4):296-298.
[12] KHAN N S,SULTAN ALLAI M,NISSAR B,et al. Genetic association of Tumour necrosis factor alpha,Interleukin-18 and Interleukin 1 beta with the risk of coronary artery disease:A casecontrol study outcome from Kashmir[J]. JAB,2018,16(4):387-393.
[13]杨顺良.麝香通心滴丸联合曲美他嗪对缺血性心力衰竭的疗效及对患者NT-proBNP及心功能的影响[J].中国医学创新,2018,15(27):4-7.
[14]张红旗,徐丹令,杨琳,等.麝香通心滴丸对大鼠血管内皮早期损伤保护作用的实验研究[J].中国临床医学,2009,16(5):669-672.
[15]郭丽,张丽,于爽.麝香通心滴丸对男性急性冠脉综合征病人血清睾酮与炎性因子的影响[J].中西医结合心脑血管病杂志,2016,14(3):284-286.
[16]万会防.麝香通心滴丸对冠心病患者血管内皮功能改善作用的研究[J].中国当代医药,2017,24(22):27-29.
[17]杨杰,张邢炜,邓亚萍,等.麝香通心滴丸对冠心病患者血管内皮功能改善作用的研究[J].中华中医药学刊,2016,34(9):2188-2190.
[18]李会英,张丹丹,周忠,等.麝香通心滴丸对血管内皮保护作用研究[J].心电与循环,2016,35(6):415-417.
[19] LIN S,CHU J F,ZHANG L,et al. Protective effects of Shexiang Tongxin Dropping Pill on pituitrin induced acute myocardial ischemia in rats[J]. Mol Med Rep,2017,16(3):3125-3132.
[20]蒋朝晖,付凌云,罗红,沈祥春. RAAS与心肌重塑及药物干预进展[J].贵州医科大学学报,2018,43(10):1143-1148.
[21]吴琪,俞军海,曹盛盛,等.麝香通心滴丸对高血压患者肾素-血管紧张素-醛固酮系统的影响[J].中华中医药学刊,2016,34(6):1351-1353.
[22]刘志超,唐倩,王保和.麝香通心滴丸治疗冠心病心绞痛作用机制研究进展[J].实用中医药杂志,2018,34(6):752-753.
[23]王金树,王力军,陈步巍.急性脑梗死患者MMP-9、hsCRP、IL-6与颈动脉粥样硬化斑块关系的临床评价[J].中西医结合心脑血管病杂志,2015,13(15):1765-1767.
[24]孙龙飞,安冬青.炎性信号通路在动脉粥样硬化中的机制与中医药干预作用研究进展[J].中国动脉硬化杂志,2015,23(11):1177-1181.
[25]宋筱靓,王帅,王凤荣.通脉降浊颗粒对动脉粥样硬化家兔脂质代谢及相关炎性因子表达的影响[J].中国中医急症,2015,24(12):2082-2086.
[26]郑新德,傅玉才,黄雨胜,等.沉默信息调节因子2相关酶1激动剂增强载脂蛋白E基因敲除小鼠动脉粥样硬化斑块的稳定性[J].汕头大学医学院学报,2015,28(3):140-143.
[27]周晓斌,杨丽霞,郭明,等.他汀类药物稳定载脂蛋白E基因敲除小鼠动脉粥样硬化斑块的作用[J].中国循环杂志,2014,29(4):296-299.
[28]牛子长,毛浩萍.麝香通心滴丸稳定家兔动脉粥样硬化斑块研究[J].辽宁中医杂志,2016,43(11):2403-2406.
[29]黄玉玮,张晓宏,李楠.麝香通心滴丸合用匹伐他汀治疗颈动脉粥样易损斑块的临床研究[J].中西医结合心脑血管病杂志,2011,9(11):1309.
[30]王怡,牛子长,何斌,等.麝香通心滴丸对稳定动脉粥样硬化斑块的机制研究[J].中西医结合心脑血管病杂志,2011,9(9):1083-1086.
[31] SUSIC D,NUNEZ E,HOSOYA K,et al. Coronary hemodynamics in aging spontaneously hypertensive and normotensive WistarKyoto rats[J]. Journal of Hypertension,1998,16(2):231-237.
[32] MATSUBARA L S,MATSUBARA B B,OKOSHI M P,et al. Myocardial fibrosis rather than hypertrophy induces diastolic dysfunction in renovascular hypertensive rats[J]. Rev can physiol pharmacol,1997,75(12):1328-1334.
[33]俞军海,曹盛盛,陈檀琦,等.麝香通心滴丸对高血压心肌纤维化的影响[J].中华中医药学刊,2016,34(7):1694-1696.
[34]姜衡,刘兵,李涛,等.冠心病基因多态性研究进展[J].国际心血管病杂志,2011,38(2):75-78.
[35]吴淳淳,杜心清.内皮型一氧化氮合酶与冠心病的研究进展[J].医学综述,2013,19(10):1756-1758.
[36] BEN ALI M,MESSAOUDI S,EZZINE H,et al. Contribution of e NOS variants to the genetic susceptibility of coronary artery disease in a Tunisian population[J]. Genet Test Mol Biomarkers,2015,19(4):203-208.
[37]朱娜,胡金飞. e NOS基因T-786C和G894T单核苷酸多态性与冠心病关系的病例对照研究[J].浙江预防医学,2016,28(1):9-12.
[38]江振洲,杨婷婷,李晓,等.药物作用靶点研究最新进展[J].药学进展,2014,38(3):161-173.
[39]张艳达,施珊岚,厉娜,等.麝香通心滴丸改善心肌梗死小鼠微循环障碍的作用机制[J].中西医结合心脑血管病杂志,2017,15(23):2969-2972.
[40] DLOUH D,HUBACEK J A. Regulatory RNAs and cardiovascular disease-with a special focus on circulating microRNAs[J].Physiol Res,2017,66(Supplementum 1):S21-S38.
[41] VAN ROOIJ E,OLSON E N. MicroRNAs:powerful new regulators of heart disease and provocative therapeutic targets[J]. J Clin Invest,2007,117(9):2369-2376.
[42]熊敏琪,贾成林,崔金刚,等.熊胆粉在麝香通心滴丸抗动脉粥样硬化中的作用机制研究[J].中国中西医结合杂志,2015,35(9):1083-1089.
[43] XIONG M Q,JIA C L,CUI J G,et al. Shexiang Tongxin dropping pill attenuates atherosclerotic lesions in ApoE deficient mouse model[J]. J Ethnopharmacol,2015,159(2):84-92.
[44] SHEN M,WU R X,ZHAO L,et al. Resveratrol attenuates ischemia/reperfusion injury in neonatal cardiomyocytes and its underlying mechanism[J]. PLo S One,2012,7(12):e51223.
[45]林珊.基于P13K/Akt信号转导通路探讨麝香通心滴丸抗心肌缺血的物质基础和作用机制[D].福州:福建中医药大学,2017.
[46] IKONOMIDIS I,KADOGLOU N N,TRITAKIS V,et al. Association of Lp-PLA2 with digital reactive hyperemia,coronary flow reserve,carotid atherosclerosis and arterial stiffness in coronary artery disease[J]. Atherosclerosis,2014,234(1):34-41.
[47]庄建芬,卢辉和.脂蛋白相关性磷脂酶A-2与冠心病及其预后的相关性分析[J].中西医结合心脑血管病杂志,2018,16(18):2688-2690.
[48] KHUSEYINOVA N,IMHOF A,ROTHENBACHER D,et al. Association between Lp-PLA2 and coronary artery disease:Focus on its relationship with lipoproteins and markers of inflammation and hemostasis[J]. Atherosclerosis,2005,182(1):181-188.
[49] IKONOMIDIS I,KADOGLOU N N,TRITAKIS V,et al. Association of Lp-PLA2 with digital reactive hyperemia,coronary flow reserve,carotid atherosclerosis and arterial stiffness in coronary artery disease[J]. Atherosclerosis,2014,234(1):34-41.
[50]陈晶晶.麝香通心滴丸对稳定型心绞痛(痰热瘀阻型)患者及AS模型大鼠Lp-PL-A2的影响[D].哈尔滨:黑龙江中医药大学,2017.
[2]付长庚,高铸烨,王培利,等.冠心病血瘀证诊断标准研究[J].中国中西医结合杂志,2015,32(9):1285-1286.
[3]曹洪涛.心血管疾病防治的中医药优势[J].西部中医药,2016,29(10):139-141.
[4] GOROG D. Coronary Heart Disease[M]. The Interventional Cardiology Training Manual. Cham:Springer International Publishing,2018:1-11.
[5]黄延锦,张平,曾颖.冠心病高危人群疾病知识认知水平及影响因素分析[J].中国护理管理,2015,13(1):51-54.
[6]韩芬,戴国华,赵晨,等. 386例冠心病心律失常住院患者中医药治疗情况调查分析[J].西部中医药,2015,28(3):86-89.
[7]田华.心电图对冠心病的诊疗意义[J].江苏实用心电学杂志,2013,22(5):823-826.
[8]刘东华,王士凯,印建荣,等.麝香通心滴丸用于稳定型心绞痛的疗效分析[J].医学理论与实践,2017,30(24):3631-3633.
[9]刘建平,廖火城,刘凌,等.麝香通心滴丸对心脏X综合征患者治疗作用的临床观察[J].中国医药科学,2018,8(12):231-233.
[10]李文华,吴晓军,李桂新,等.麝香通心滴丸治疗冠心病心绞痛的系统评价[J].西北国防医学杂志,2018,39(5):281-284.
[11]汪志忠,黎红华.动脉粥样硬化与炎性因子[J].中国神经免疫学和神经病学杂志,2011,18(4):296-298.
[12] KHAN N S,SULTAN ALLAI M,NISSAR B,et al. Genetic association of Tumour necrosis factor alpha,Interleukin-18 and Interleukin 1 beta with the risk of coronary artery disease:A casecontrol study outcome from Kashmir[J]. JAB,2018,16(4):387-393.
[13]杨顺良.麝香通心滴丸联合曲美他嗪对缺血性心力衰竭的疗效及对患者NT-proBNP及心功能的影响[J].中国医学创新,2018,15(27):4-7.
[14]张红旗,徐丹令,杨琳,等.麝香通心滴丸对大鼠血管内皮早期损伤保护作用的实验研究[J].中国临床医学,2009,16(5):669-672.
[15]郭丽,张丽,于爽.麝香通心滴丸对男性急性冠脉综合征病人血清睾酮与炎性因子的影响[J].中西医结合心脑血管病杂志,2016,14(3):284-286.
[16]万会防.麝香通心滴丸对冠心病患者血管内皮功能改善作用的研究[J].中国当代医药,2017,24(22):27-29.
[17]杨杰,张邢炜,邓亚萍,等.麝香通心滴丸对冠心病患者血管内皮功能改善作用的研究[J].中华中医药学刊,2016,34(9):2188-2190.
[18]李会英,张丹丹,周忠,等.麝香通心滴丸对血管内皮保护作用研究[J].心电与循环,2016,35(6):415-417.
[19] LIN S,CHU J F,ZHANG L,et al. Protective effects of Shexiang Tongxin Dropping Pill on pituitrin induced acute myocardial ischemia in rats[J]. Mol Med Rep,2017,16(3):3125-3132.
[20]蒋朝晖,付凌云,罗红,沈祥春. RAAS与心肌重塑及药物干预进展[J].贵州医科大学学报,2018,43(10):1143-1148.
[21]吴琪,俞军海,曹盛盛,等.麝香通心滴丸对高血压患者肾素-血管紧张素-醛固酮系统的影响[J].中华中医药学刊,2016,34(6):1351-1353.
[22]刘志超,唐倩,王保和.麝香通心滴丸治疗冠心病心绞痛作用机制研究进展[J].实用中医药杂志,2018,34(6):752-753.
[23]王金树,王力军,陈步巍.急性脑梗死患者MMP-9、hsCRP、IL-6与颈动脉粥样硬化斑块关系的临床评价[J].中西医结合心脑血管病杂志,2015,13(15):1765-1767.
[24]孙龙飞,安冬青.炎性信号通路在动脉粥样硬化中的机制与中医药干预作用研究进展[J].中国动脉硬化杂志,2015,23(11):1177-1181.
[25]宋筱靓,王帅,王凤荣.通脉降浊颗粒对动脉粥样硬化家兔脂质代谢及相关炎性因子表达的影响[J].中国中医急症,2015,24(12):2082-2086.
[26]郑新德,傅玉才,黄雨胜,等.沉默信息调节因子2相关酶1激动剂增强载脂蛋白E基因敲除小鼠动脉粥样硬化斑块的稳定性[J].汕头大学医学院学报,2015,28(3):140-143.
[27]周晓斌,杨丽霞,郭明,等.他汀类药物稳定载脂蛋白E基因敲除小鼠动脉粥样硬化斑块的作用[J].中国循环杂志,2014,29(4):296-299.
[28]牛子长,毛浩萍.麝香通心滴丸稳定家兔动脉粥样硬化斑块研究[J].辽宁中医杂志,2016,43(11):2403-2406.
[29]黄玉玮,张晓宏,李楠.麝香通心滴丸合用匹伐他汀治疗颈动脉粥样易损斑块的临床研究[J].中西医结合心脑血管病杂志,2011,9(11):1309.
[30]王怡,牛子长,何斌,等.麝香通心滴丸对稳定动脉粥样硬化斑块的机制研究[J].中西医结合心脑血管病杂志,2011,9(9):1083-1086.
[31] SUSIC D,NUNEZ E,HOSOYA K,et al. Coronary hemodynamics in aging spontaneously hypertensive and normotensive WistarKyoto rats[J]. Journal of Hypertension,1998,16(2):231-237.
[32] MATSUBARA L S,MATSUBARA B B,OKOSHI M P,et al. Myocardial fibrosis rather than hypertrophy induces diastolic dysfunction in renovascular hypertensive rats[J]. Rev can physiol pharmacol,1997,75(12):1328-1334.
[33]俞军海,曹盛盛,陈檀琦,等.麝香通心滴丸对高血压心肌纤维化的影响[J].中华中医药学刊,2016,34(7):1694-1696.
[34]姜衡,刘兵,李涛,等.冠心病基因多态性研究进展[J].国际心血管病杂志,2011,38(2):75-78.
[35]吴淳淳,杜心清.内皮型一氧化氮合酶与冠心病的研究进展[J].医学综述,2013,19(10):1756-1758.
[36] BEN ALI M,MESSAOUDI S,EZZINE H,et al. Contribution of e NOS variants to the genetic susceptibility of coronary artery disease in a Tunisian population[J]. Genet Test Mol Biomarkers,2015,19(4):203-208.
[37]朱娜,胡金飞. e NOS基因T-786C和G894T单核苷酸多态性与冠心病关系的病例对照研究[J].浙江预防医学,2016,28(1):9-12.
[38]江振洲,杨婷婷,李晓,等.药物作用靶点研究最新进展[J].药学进展,2014,38(3):161-173.
[39]张艳达,施珊岚,厉娜,等.麝香通心滴丸改善心肌梗死小鼠微循环障碍的作用机制[J].中西医结合心脑血管病杂志,2017,15(23):2969-2972.
[40] DLOUH D,HUBACEK J A. Regulatory RNAs and cardiovascular disease-with a special focus on circulating microRNAs[J].Physiol Res,2017,66(Supplementum 1):S21-S38.
[41] VAN ROOIJ E,OLSON E N. MicroRNAs:powerful new regulators of heart disease and provocative therapeutic targets[J]. J Clin Invest,2007,117(9):2369-2376.
[42]熊敏琪,贾成林,崔金刚,等.熊胆粉在麝香通心滴丸抗动脉粥样硬化中的作用机制研究[J].中国中西医结合杂志,2015,35(9):1083-1089.
[43] XIONG M Q,JIA C L,CUI J G,et al. Shexiang Tongxin dropping pill attenuates atherosclerotic lesions in ApoE deficient mouse model[J]. J Ethnopharmacol,2015,159(2):84-92.
[44] SHEN M,WU R X,ZHAO L,et al. Resveratrol attenuates ischemia/reperfusion injury in neonatal cardiomyocytes and its underlying mechanism[J]. PLo S One,2012,7(12):e51223.
[45]林珊.基于P13K/Akt信号转导通路探讨麝香通心滴丸抗心肌缺血的物质基础和作用机制[D].福州:福建中医药大学,2017.
[46] IKONOMIDIS I,KADOGLOU N N,TRITAKIS V,et al. Association of Lp-PLA2 with digital reactive hyperemia,coronary flow reserve,carotid atherosclerosis and arterial stiffness in coronary artery disease[J]. Atherosclerosis,2014,234(1):34-41.
[47]庄建芬,卢辉和.脂蛋白相关性磷脂酶A-2与冠心病及其预后的相关性分析[J].中西医结合心脑血管病杂志,2018,16(18):2688-2690.
[48] KHUSEYINOVA N,IMHOF A,ROTHENBACHER D,et al. Association between Lp-PLA2 and coronary artery disease:Focus on its relationship with lipoproteins and markers of inflammation and hemostasis[J]. Atherosclerosis,2005,182(1):181-188.
[49] IKONOMIDIS I,KADOGLOU N N,TRITAKIS V,et al. Association of Lp-PLA2 with digital reactive hyperemia,coronary flow reserve,carotid atherosclerosis and arterial stiffness in coronary artery disease[J]. Atherosclerosis,2014,234(1):34-41.
[50]陈晶晶.麝香通心滴丸对稳定型心绞痛(痰热瘀阻型)患者及AS模型大鼠Lp-PL-A2的影响[D].哈尔滨:黑龙江中医药大学,2017.